Science
Fat accumulation, chronic inflammation, and progressive fibrotic activity make Non-Alcoholic Steatohepatitis a major focus within metabolic disease research. Pharmaceutical and biotech organisations therefore require reliable in vitro systems which support accurate evaluation of therapeutic candidates across early discovery stages. Hepatic cell models and disease-relevant assay platforms now assist scientists who investigate lipid metabolism, inflammatory signalling, and fibrotic response under controlled laboratory conditions. Strong translational relevance also remains essential for candidate selection and mechanism analysis prior to clinical progression. Through specialised assay expertise,Cellomatics Biosciences supports research programmes which target NASH and related metabolic liver disorders. The company enables biologically relevant screening and pathway-focused investigation for organisations which seek dependable preclinical insight during therapeutic development.